title: The shifting landscape of safety pharmacology in 2015.
abstract: The relative importance of the discipline of safety pharmacology (which integrates physiology, pharmacologyand toxicology) has evolved since the incorporation of the Safety Pharmacology Society (SPS) as an entity on August 10, 2000. Safety pharmacology (SP), as a synthesis of these other fields of knowledge, is concerned with characterizing the safety profile (or potential undesirable pharmacodynamic effects) of new chemical entities (NCEs) and biologicals. Initially focused on the issue of drug-induced QT prolongation it has developed into an important discipline over the past 15years with expertise beyond its initial focus on torsades de pointes (TdP). It has become a repository for interrogation of models for drug safety studies and innovative non-clinical model development, validation and implementation. Thus, while safety pharmacology consists of the triumvirate obligatory cardiovascular, central nervous system (CNS) and respiratory system core battery studies it also involves assessing drug effects on numerous other physiological systems (e.g., ocular, auditory, renal, gastrointestinal, blood, immune) leveraging emerging new technologies in a wide range of non-clinical drug safety testing models. As with previous editorials that preface the themed issue on safety pharmacology methods published in the Journal of Pharmacological and Toxicological Methods (JPTM), we highlight here the content derived from the most recent (2014) SPS meeting held in Washington, DC. The dynamics of the discipline remain fervent and method development, extension and refinement are reflected in the content. This issue of the JPTM continues the tradition of providing a publication summary of articles (reviews, commentaries and methods) with impact on the discipline of safety pharmacology.
authors.affiliation: CiToxLAB Research Inc., 445 Armand Frappier, Laval, QC H7V 4B3, Canada. Electronic address: mkpugsley@yahoo.com.
authors.forename: Michael K
authors.initials: MK
authors.lastname: Pugsley
authors.affiliation: CiToxLAB Research Inc., 445 Armand Frappier, Laval, QC H7V 4B3, Canada.
authors.forename: Simon
authors.initials: S
authors.lastname: Authier
authors.affiliation: Columbia, MO, United States.
authors.forename: Michael
authors.initials: M
authors.lastname: Stonerook
authors.affiliation: Cardiovascular Division, Rayne Institute, St Thomas' Hospital, London SE17EH, UK.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Curtis
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008962:Models, Theoretical; D010600:Pharmacology / Q000458:organization & administration*; D014116:Toxicology / Q000458:organization & administration